MX2017005236A - Profarmacos de carbidopa y l-dopa y metodos de uso. - Google Patents

Profarmacos de carbidopa y l-dopa y metodos de uso.

Info

Publication number
MX2017005236A
MX2017005236A MX2017005236A MX2017005236A MX2017005236A MX 2017005236 A MX2017005236 A MX 2017005236A MX 2017005236 A MX2017005236 A MX 2017005236A MX 2017005236 A MX2017005236 A MX 2017005236A MX 2017005236 A MX2017005236 A MX 2017005236A
Authority
MX
Mexico
Prior art keywords
carbidopa
disease
treat parkinson
prodrug
dopa
Prior art date
Application number
MX2017005236A
Other languages
English (en)
Other versions
MX381069B (es
Inventor
A Matulenko Mark
A Voight Eric
J Stella Valentino
Lao Yanbin
Lou Xiaochun
S Chan Vincent
Wang Zhi
Huang Ye
G Zhang Geoff
Cardinal-David Benoit
E Dempah Kassibla
P Enright Brian
F Henry Rodger
Ho Raimundo
D Huters Alexander
C Klix Russell
W Krabbe Scott
R Kym Philip
E Mackey Sean
T Mayer Peter
P Miller Christopher
Stambuli James
Original Assignee
Abbvie Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=54478240&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2017005236(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Abbvie Inc filed Critical Abbvie Inc
Publication of MX2017005236A publication Critical patent/MX2017005236A/es
Publication of MX381069B publication Critical patent/MX381069B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/06—Phosphorus compounds without P—C bonds
    • C07F9/08—Esters of oxyacids of phosphorus
    • C07F9/09—Esters of phosphoric acids
    • C07F9/094—Esters of phosphoric acids with arylalkanols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
    • A61K31/6615—Compounds having two or more esterified phosphorus acid groups, e.g. inositol triphosphate, phytic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C281/00—Derivatives of carbonic acid containing functional groups covered by groups C07C269/00 - C07C279/00 in which at least one nitrogen atom of these functional groups is further bound to another nitrogen atom not being part of a nitro or nitroso group
    • C07C281/02—Compounds containing any of the groups, e.g. carbazates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
    • C07C309/01—Sulfonic acids
    • C07C309/02—Sulfonic acids having sulfo groups bound to acyclic carbon atoms
    • C07C309/24—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of a carbon skeleton containing six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C47/00—Compounds having —CHO groups
    • C07C47/20—Unsaturated compounds having —CHO groups bound to acyclic carbon atoms
    • C07C47/277—Unsaturated compounds having —CHO groups bound to acyclic carbon atoms containing ether groups, groups, groups, or groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/06—Phosphorus compounds without P—C bonds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

La presente descripción se refiere a (a) profármacos de carbidopa, (b) combinaciones y composiciones farmacéuticas que comprenden un profármaco de carbidopa y/o un profármaco de L-dopa, y (c) métodos para tratar mal de Parkinson y afecciones asociadas que comprenden administrar un profármaco de carbidopa y un profármaco de L-dopa al sujeto con mal de Parkinson.
MX2017005236A 2014-10-21 2015-10-21 Profármacos de carbidopa y l-dopa y métodos de uso. MX381069B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462066771P 2014-10-21 2014-10-21
PCT/US2015/056686 WO2016065019A1 (en) 2014-10-21 2015-10-21 Carbidopa and l-dopa prodrugs and their use to treat parkinson's disease

Publications (2)

Publication Number Publication Date
MX2017005236A true MX2017005236A (es) 2017-07-26
MX381069B MX381069B (es) 2025-03-12

Family

ID=54478240

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2021003840A MX393568B (es) 2014-10-21 2015-10-21 Profarmacos de carbidopa y l-dopa y metodos de uso
MX2017005236A MX381069B (es) 2014-10-21 2015-10-21 Profármacos de carbidopa y l-dopa y métodos de uso.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MX2021003840A MX393568B (es) 2014-10-21 2015-10-21 Profarmacos de carbidopa y l-dopa y metodos de uso

Country Status (37)

Country Link
US (7) US9446059B2 (es)
EP (3) EP3569587A1 (es)
JP (6) JP6567049B2 (es)
KR (3) KR20240113982A (es)
CN (4) CN107206013A (es)
AR (1) AR102389A1 (es)
AU (4) AU2015335941B2 (es)
BR (1) BR112017008198B1 (es)
CA (1) CA2965379A1 (es)
CY (2) CY1121826T1 (es)
DK (1) DK3209302T3 (es)
ES (1) ES2739536T3 (es)
FI (1) FIC20230014I1 (es)
FR (1) FR23C1035I2 (es)
HR (1) HRP20191285T1 (es)
HU (2) HUE044115T2 (es)
IL (3) IL251829B (es)
LT (2) LT3209302T (es)
LU (1) LUC00304I2 (es)
MX (2) MX393568B (es)
MY (1) MY189519A (es)
NL (1) NL301224I2 (es)
NO (1) NO2023013I1 (es)
PH (1) PH12017500746B1 (es)
PL (1) PL3209302T3 (es)
PT (1) PT3209302T (es)
RS (1) RS58972B1 (es)
RU (2) RU2021103000A (es)
SA (1) SA521421115B1 (es)
SG (1) SG11201703170RA (es)
SI (1) SI3209302T1 (es)
SM (1) SMT201900376T1 (es)
TR (1) TR201908296T4 (es)
TW (2) TWI755257B (es)
UA (1) UA120437C2 (es)
WO (1) WO2016065019A1 (es)
ZA (1) ZA201702760B (es)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015136538A1 (en) 2014-03-13 2015-09-17 Neuroderm Ltd Dopa decarboxylase inhibitor compositions
US10258585B2 (en) 2014-03-13 2019-04-16 Neuroderm, Ltd. DOPA decarboxylase inhibitor compositions
RU2021103000A (ru) 2014-10-21 2021-03-01 Эббви Инк. Пролекарства карбидопа и l-dopa и их применение для лечения болезни паркинсона
JP2019515908A (ja) * 2016-04-20 2019-06-13 アッヴィ・インコーポレイテッド カルビドパ及びｌ−ドパプロドラッグ並びに使用方法
WO2017223182A1 (en) * 2016-06-22 2017-12-28 Medchem Partners, Llc. Nitric oxide donors
WO2018154447A1 (en) * 2017-02-21 2018-08-30 Neuroderm Ltd Dopa decarboxylase inhibitor compositions
US20180311238A1 (en) * 2017-04-28 2018-11-01 Saniona A/S Selective Agonist Of a6 Containing nAChRs
WO2019097120A1 (en) 2017-11-16 2019-05-23 Orion Corporation New use and pharmaceutical dosage forms
AR113908A1 (es) 2017-11-24 2020-06-24 H Lundbeck As Profármacos de catecolamina para uso en el tratamiento de la enfermedad de parkinson
CN110294789A (zh) * 2018-03-21 2019-10-01 海南大学 含多巴寡肽的合成方法及其在抗帕金森病前药方面的应用
SG11202101817UA (en) 2018-09-13 2021-03-30 Univ Canberra Methods of inhibition
EP3880210A1 (en) 2018-11-15 2021-09-22 Abbvie Inc. Pharmaceutical formulations for subcutaneous administration
WO2020178810A1 (en) * 2019-03-04 2020-09-10 Neuroderm, Ltd. Pharmaceutical compositions comprising levodopa amide derivatives and uses thereof
US11168056B2 (en) 2019-05-20 2021-11-09 H. Lundbeck A/S Process for the manufacturing of (6aR,10aR)-7-propyl-6,6a,7,8,9,10,10a,11-octahydro-[1,3]dioxolo[4′,5′:5,6]benzo[1,2-G]quinoline and (4aR,10aR)-1-propyl-1,2,3,4,4a,5,10,10a-octahydro-benzo[G]quinoline-6,7-diol
US11130775B2 (en) 2019-05-20 2021-09-28 H. Lundbeck A/S Solid forms of (2S,3S,4S,5R,6S)-3,4,5-trihydroxy-6-(((4aR,10aR)-7-hydroxy-1-propyl-1,2,3,4,4A,5,10,10A-octahydrobenzo[g]quinolin-6-yl)oxy)tetrahydro-2H-pyran-2-carboxylic acid
US11104697B2 (en) 2019-05-20 2021-08-31 H. Lundbeck A/S Process for the manufacture of (2S,3S,4S,5R,6S)-3,4,5-trihydroxy-6-(((4AR,10AR)-7-hydroxy-1- propyl-1,2,3,4,4A,5,10,10A-octahydrobenzo[g]quinolin-6-yl)oxy)tetrahydro-2H-pyran-2-carboxylic acid
US11111263B2 (en) 2019-05-20 2021-09-07 H. Lundbeck A/S Process for the manufacture of (2S,3S,4S,5R,6S)-3,4,5-trihydroxy-6-(((4aR,10aR)-7-hydroxy-1-propyl-1,2,3,4,4a,5,10,10a-octahydrobenzo[g]quinolin-6-yl)oxy)tetrahydro-2H-pyran-2-carboxylic acid
EP3972600B1 (en) 2019-05-21 2026-02-18 H. Lundbeck A/S Catecholamine carbamate prodrugs for use in the treatment of parkinson s disease
US12391650B2 (en) 2019-05-21 2025-08-19 H. Lundbeck A/S Catecholamine prodrugs for use in the treatment of Parkinson's disease
CN113677675B (zh) 2019-05-21 2024-07-26 H.隆德贝克有限公司 用于治疗帕金森病的新儿茶酚胺前药
CN113727979B (zh) 2019-05-21 2024-09-20 H.隆德贝克有限公司 用于治疗帕金森病的新儿茶酚胺前药
US11844754B2 (en) 2020-11-17 2023-12-19 Neuroderm, Ltd. Methods for treatment of Parkinson's disease
US11213502B1 (en) 2020-11-17 2022-01-04 Neuroderm, Ltd. Method for treatment of parkinson's disease
US11331293B1 (en) 2020-11-17 2022-05-17 Neuroderm, Ltd. Method for treatment of Parkinson's disease
EP4223288B1 (en) 2022-02-07 2024-03-06 Berlirem GmbH Novel kit of pharmaceutical preparations for the treatment of parkinson's disease
US12161612B2 (en) 2023-04-14 2024-12-10 Neuroderm, Ltd. Methods and compositions for reducing symptoms of Parkinson's disease

Family Cites Families (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3132171A (en) * 1962-06-18 1964-05-05 Strong Cobb Arner Inc 3, 4-diphosphatophenyl-alanine and process for making same
US4016288A (en) * 1975-08-13 1977-04-05 Merck & Co., Inc. Compositions and method of treating hypertension
DD230865B1 (de) * 1982-08-09 1987-05-20 Dresden Arzneimittel Verfahren zur herstellung von hydrazinocarbonsaeurederivaten durch n-aminierung von aminocarbonsaeurederivaten
US4618484A (en) 1983-03-30 1986-10-21 Yale University Composition and method for treatment of melanomas
US4508706A (en) * 1983-03-30 1985-04-02 Yale University Composition for increasing melanin in mammalian skin and hair
IT1213182B (it) * 1984-06-25 1989-12-14 Simes Derivati di composti a struttura catecolamminica.
US4616484A (en) 1984-11-30 1986-10-14 Kysor Industrial Corporation Vehicle refrigerant heating and cooling system
IT1200427B (it) 1985-03-22 1989-01-18 Afros Spa Procedimento ed impianto per lo stampaggio di pezzi in materiale plastico espanso,con parti o inserti preformati a spruzzo nello stesso stampo di formatura
JPH02138A (ja) 1987-09-18 1990-01-05 Banyu Pharmaceut Co Ltd Ｌ‐ドーパ誘導体
IT1226727B (it) 1988-07-29 1991-02-05 Simes Farmaci precursori della dopamina.
ES2070994T3 (es) * 1989-04-20 1995-06-16 Zambon Spa Profarmaco de dopamina.
GB9102812D0 (en) 1991-02-11 1991-03-27 Enzymatix Ltd Compounds
IT1255471B (it) 1992-07-30 1995-11-02 Zambon Spa Derivati di catecolammine,processo per la loro preparazione e composizioni farmaceutiche che li contengono
SE9203594D0 (sv) 1992-11-30 1992-11-30 Christer Nystroem Laekemedel i dispersa system
WO1999024442A1 (en) * 1997-11-12 1999-05-20 Ariad Pharmaceuticals, Inc. Novel signal transduction inhibitors, compositions containing them
US6365180B1 (en) 1998-01-20 2002-04-02 Glenn A. Meyer Oral liquid compositions
US6204257B1 (en) 1998-08-07 2001-03-20 Universtiy Of Kansas Water soluble prodrugs of hindered alcohols
KR20050016449A (ko) * 2002-05-29 2005-02-21 임팩스 라보라토리즈, 인코포레이티드 레보도파/카르비도파의 즉시 방출 및 제어 방출 조합 투여형
US20050203061A1 (en) 2002-06-20 2005-09-15 Shinya Yamashita Prodrug, medicinal utilization thereof and process for producing the same
AU2003293423A1 (en) 2002-12-06 2004-06-30 Xenoport, Inc. Carbidopa prodrugs and uses thereof
WO2004069146A2 (en) 2003-02-07 2004-08-19 Yissum Research Development Company Of The Hebrew University Of Jerusalem L-dopa amide derivatives and uses thereof
ES2360759T3 (es) * 2003-08-29 2011-06-08 Centocor Ortho Biotech Inc. Composiciones farmacéuticas y procedimiento de utilización de la levodopa y de la carbidopa.
CA2536175C (en) 2003-08-29 2013-05-28 Transform Pharmaceuticals, Inc. Pharmaceutical compositions and method of using levodopa and carbidopa
JP2007509973A (ja) 2003-10-31 2007-04-19 アルザ・コーポレーシヨン 増強された吸収のための組成物および投与形態物
JP4781352B2 (ja) * 2004-06-04 2011-09-28 ゼノポート，インコーポレーテッド レボドパプロドラッグおよびその組成物ならびにその使用
ES2402552T3 (es) 2004-07-06 2013-05-06 Abbott Laboratories Profármacos de inhibidores de proteasa de VIH
AU2006322051B2 (en) * 2005-12-05 2011-09-29 Xenoport, Inc. Levodopa prodrug mesylate, compositions thereof, and uses thereof
KR20090057349A (ko) * 2006-05-31 2009-06-05 솔베이 파머슈티컬스 게엠베하 레보도파／칼비도파의 ２４시간의 장기간 장내투여
AU2007259256A1 (en) * 2006-06-16 2007-12-21 Solvay Pharmaceuticals B.V. Combination preparations comprising bifeprunox and L-DOPA
US7709527B2 (en) 2006-12-21 2010-05-04 Xenoport, Inc. Levodopa dimethyl-substituted diester prodrugs compositions, and methods of use
GB0713189D0 (en) 2007-07-06 2007-08-15 Proximagen Ltd Amino acid derivatives
RU2485947C2 (ru) * 2008-02-06 2013-06-27 Вокхардт Рисерч Сентер Фармацевтические композиции энтакапона, леводопы и карбидопы с улучшенной биодоступностью
CA2724877C (en) 2008-05-20 2016-09-13 Neurogesx, Inc. Water-soluble acetaminophen analogs
SG10201505101VA (en) 2009-05-19 2015-07-30 Neuroderm Ltd Compositions For Continuous Administration Of Dopa Decarboxylase Inhibitors
US20130253056A1 (en) 2009-05-19 2013-09-26 Neuroderm, Ltd. Continuous Administration of Levodopa and/or Dopa Decarboxylase Inhibitors and Compositions for Same
JP2013520521A (ja) 2009-11-09 2013-06-06 ゼノポート，インコーポレーテッド レボドパプロドラッグの医薬組成物及び経口剤形並びに使用方法
WO2011109767A2 (en) 2010-03-04 2011-09-09 University Of Notre Dame Du Lac Gelatinase inhibitors and prodrugs
SI2640358T1 (en) 2010-11-15 2018-05-31 Neuroderm Ltd. Continuous administration of L-dopa, dopamine decarboxylase inhibitors, catechol-O-methyl transferase inhibitors, and compositions thereof
MX342798B (es) 2010-12-02 2016-10-13 Ono Pharmaceutical Co Compuesto de ácido (2s)-2-amino-3-(3,4-bis((2-(benzoiloxi)-2-metil propanoil)oxi)-fenil)propanóico y uso médico del mismo.
SG191090A1 (en) 2010-12-10 2013-07-31 Synagile Corp Subcutaneously infusible levodopa prodrug compositions and methods of infusion
US8765189B2 (en) * 2011-05-13 2014-07-01 Howmedica Osteonic Corp. Organophosphorous and multivalent metal compound compositions and methods
KR20130070371A (ko) * 2011-12-19 2013-06-27 울산대학교 산학협력단 퇴행성 신경질환 예방 또는 치료용 조성물
CN105209029A (zh) 2013-03-13 2015-12-30 纽罗德姆有限公司 帕金森病的治疗方法
CN105143174B (zh) 2013-03-15 2021-01-12 苏州泰飞尔医药有限公司 治疗帕金森疾病的新型高穿透力药物及其药物组合物
RU2021103000A (ru) 2014-10-21 2021-03-01 Эббви Инк. Пролекарства карбидопа и l-dopa и их применение для лечения болезни паркинсона
MA41377A (fr) 2015-01-20 2017-11-28 Abbvie Inc Gel intestinal de lévodopa et de carbidona et procédés d'utilisation
JP2019515908A (ja) 2016-04-20 2019-06-13 アッヴィ・インコーポレイテッド カルビドパ及びｌ−ドパプロドラッグ並びに使用方法
EP3518920A1 (en) 2016-09-29 2019-08-07 Berlirem GmbH L-dopa derivatives for the treatment of neurological diseases
WO2018154447A1 (en) 2017-02-21 2018-08-30 Neuroderm Ltd Dopa decarboxylase inhibitor compositions

Also Published As

Publication number Publication date
CN111494395B (zh) 2024-06-21
HRP20191285T1 (hr) 2019-10-18
JP6932227B2 (ja) 2021-09-08
JP7688087B2 (ja) 2025-06-03
DK3209302T3 (da) 2019-05-13
US20180079762A1 (en) 2018-03-22
CN107206013A (zh) 2017-09-26
US20230106081A1 (en) 2023-04-06
PH12017500746B1 (en) 2021-12-15
IL251829A0 (en) 2017-06-29
AU2015335941B2 (en) 2021-04-01
ES2739536T3 (es) 2020-01-31
TWI718999B (zh) 2021-02-21
JP2023174770A (ja) 2023-12-08
LUC00304I2 (es) 2025-09-22
RU2021103000A (ru) 2021-03-01
TWI755257B (zh) 2022-02-11
SG11201703170RA (en) 2017-05-30
NL301224I1 (es) 2023-03-29
WO2016065019A1 (en) 2016-04-28
IL268885A (en) 2019-10-31
KR20170071599A (ko) 2017-06-23
RS58972B1 (sr) 2019-08-30
IL276493A (en) 2020-09-30
NZ730996A (en) 2024-04-26
CA2965379A1 (en) 2016-04-28
US10730895B2 (en) 2020-08-04
HUE044115T2 (hu) 2019-10-28
NZ769153A (en) 2024-04-26
RU2017117413A (ru) 2018-11-26
AU2021201414A1 (en) 2021-03-25
LTPA2023519I1 (es) 2023-06-26
SA521421115B1 (ar) 2022-03-01
CN111362980B (zh) 2022-10-18
AU2023210650A1 (en) 2023-08-24
CY2023010I2 (el) 2023-06-09
KR20240113982A (ko) 2024-07-23
ZA201702760B (en) 2022-05-25
SI3209302T1 (sl) 2019-06-28
JP2020189864A (ja) 2020-11-26
JP2025118978A (ja) 2025-08-13
EP3569587A1 (en) 2019-11-20
FIC20230014I1 (fi) 2023-03-31
JP2021183628A (ja) 2021-12-02
HUS2300009I1 (hu) 2023-03-28
UA120437C2 (uk) 2019-12-10
LT3209302T (lt) 2019-06-10
US20200262852A1 (en) 2020-08-20
TR201908296T4 (tr) 2019-06-21
CN111454290A (zh) 2020-07-28
TW202131931A (zh) 2021-09-01
CN111494395A (zh) 2020-08-07
JP6750076B2 (ja) 2020-09-02
BR112017008198B1 (pt) 2021-02-09
AU2025238004A1 (en) 2025-10-16
US9446059B2 (en) 2016-09-20
JP2017537066A (ja) 2017-12-14
CY2023010I1 (el) 2023-06-09
RU2017117413A3 (es) 2019-05-30
BR112017008198A2 (pt) 2017-12-26
FR23C1035I1 (fr) 2023-12-08
EP3209302A1 (en) 2017-08-30
NL301224I2 (nl) 2023-08-16
US11091507B2 (en) 2021-08-17
RU2743347C2 (ru) 2021-02-17
FR23C1035I2 (fr) 2025-04-18
US20160106765A1 (en) 2016-04-21
LTC3209302I2 (es) 2025-10-10
AU2021201414B2 (en) 2023-05-11
EP3209302B1 (en) 2019-04-24
US20190375770A1 (en) 2019-12-12
KR102537018B1 (ko) 2023-05-30
MY189519A (en) 2022-02-16
CY1121826T1 (el) 2020-07-31
PL3209302T3 (pl) 2019-10-31
IL268885B (en) 2020-08-31
MX2021003840A (es) 2022-06-30
JP6567049B2 (ja) 2019-08-28
SMT201900376T1 (it) 2019-09-09
AR102389A1 (es) 2017-02-22
AU2015335941A1 (en) 2017-05-04
CN111454290B (zh) 2022-12-23
US20220153765A1 (en) 2022-05-19
PH12017500746A1 (en) 2017-10-30
CN111362980A (zh) 2020-07-03
MX393568B (es) 2025-03-24
KR20230066484A (ko) 2023-05-15
PT3209302T (pt) 2019-07-19
NO2023013I1 (no) 2023-03-20
JP2019218356A (ja) 2019-12-26
MX381069B (es) 2025-03-12
EP4186510A1 (en) 2023-05-31
IL251829B (en) 2019-09-26
US10174061B2 (en) 2019-01-08
US20160362431A1 (en) 2016-12-15
TW201630924A (zh) 2016-09-01

Similar Documents

Publication Publication Date Title
MX2017005236A (es) Profarmacos de carbidopa y l-dopa y metodos de uso.
WO2017184871A9 (en) Carbidopa and l-dopa prodrugs and methods of use
BR112017009497A2 (pt) polinucleotídeos de aadc para o tratamento da doença de parkinson
MX369041B (es) Proteinas quimericas tipo fosfatasa alcalina.
CO2018003224A2 (es) Formulaciones de aminoacidos de liberacion modificada administradas oralmente
UY36224A (es) Compuestos tricíclicos de imidazo-pirimidinona
UY35276A (es) Nuevos compuestos que inhiben la actividad de Lp-PLA2
MX386055B (es) Uso de medicamentos para disminuir la evolución de la enfermedad de parkinson.
CO2019008103A2 (es) Composiciones farmacéuticas para terapia de combinación
CL2017003124A1 (es) Moduladores alostéricos positivos del receptor de m2 muscarínico
BR112017014598A2 (pt) métodos e usos para hidrólise de queratina
CL2016000019A1 (es) Compuestos derivados de dihidroxifenilo deuterado o una sal de los mismos; composición farmacéutica que los comprende y su uso para el tratamiento de trastornos mediados por neurotransmisores tales como hipotensión, trastornos del sueño, enfermedad de alzheimer y depresión.
BR112018072255A2 (pt) azasteroides para tratamento de tuberculose
CL2019002174A1 (es) Composición que comprende capecitabina de liberación inmediata y liberación prolongada.
BR112018077112A2 (pt) uso de liso-gb1 como alvo capaz de ser modulado por um fármaco
BR112018012313A2 (pt) composições que compreendem 15-hepe e métodos para uso das mesmas
AR102995A1 (es) Uso de ligandos del receptor sigma en la osteoartritis
IN2013MU03855A (es)